학술논문
Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
Document Type
Review Article
Author
Source
In Research and Practice in Thrombosis and Haemostasis May 2024 8(4)
Subject
Language
ISSN
2475-0379